Zotarolimus-eluting stents

Source：Medtronic, Inc Release Date：2013-11-05 424

Medical Equipment

Add to Favorites

In studies of Medtronic stents, patients who interrupted dual antiplatelet therapy early saw no increased thrombosis risk

NEW data presented at TCT and published by JAMA has affirmed excellent safety profile of zotarolimus-eluting stents. According to findings from several studies presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) and subsequently interrupted their dual antiplatelet therapy (DAPT) earlier than current guidelines recommend experienced no increased risk of stent thrombosis at one year or more of follow up. Both devices elute the drug zotarolimus to reduce the risk of restenosis

Resolute Integrity DES expanded on balloon (Photo © Medtronic)

Medtronic International Ltd
Singapore
T: +65 6436 5000

Medtronic Medical Appliance Technology & Service (Shanghai) Limited
China
T: +86 10 5869 8989

Adidas Fotballsko

Add to Favorites